Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMeBAC: Benzylpenicillin vs cloxacillin for penicillin-susceptible Staphylococcus aureus bacteraemia
2023-506860-15-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Feb 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Staphylococcal bacteremia comparing Benzylpenicillin with Cloxacillin (2 arms). Primary endpoint: Alive at day 90 without complications. Planned start Feb 2024; status: authorised.
02
Drugs
benzylpenicillincloxacillin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on 2023-506860-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506860-15-00.